Results 51 to 60 of about 9,498 (160)
Microbial Biotechnology, Volume 19, Issue 4, April 2026.The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley +1 more source
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
Infection and Drug Resistance, 2019 Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj
Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.ABSTRACT Approximately 8.8 million people are living with chronic hepatitis C virus (HCV) in Pakistan. We assessed factors related to health‐related quality of life (HRQoL) among the general population screened for HCV and calculated the national burden in quality‐adjusted life years (QALYs).
Siwaporn Niyomsri +24 more
wiley +1 more source
Hepatitis E Virus Drug Development
Viruses, 2019 Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in ...
Volker Kinast +3 more
doaj +1 more source
Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.ABSTRACT Prisons offer a critical opportunity for hepatitis C virus (HCV) elimination, yet current data from Danish correctional facilities are sparse. We conducted a cross‐sectional study in 16 prisons across Eastern Denmark between October 2022 and August 2024, enrolling 651 incarcerated individuals.
Jonas Demant +10 more
wiley +1 more source
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
One Health & Risk Management, 2020 Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU +2 more
doaj +1 more source
Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management
IUBMB Life, Volume 78, Issue 3, March 2026.ABSTRACT Pulmonary arterial hypertension (PAH) is a severe, progressive disease characterized by elevated pulmonary arterial pressure and increased vascular resistance. This hemodynamic strain forces the right ventricle to pump against a high‐pressure system, ultimately leading to right‐sided heart failure and death.
Federica Davì +5 more
wiley +1 more source
Molecules, 2019 A simple, fast and highly sensitive RP-UPLC-MS/MS method was developed and validated for the simultaneous determination of sofosbuvir (SR) and its metabolite GS331007 in human plasma using ketotifen as an internal standard (IS).
Mohammad H. Semreen +3 more
doaj +1 more source
Portal Hypertension &Cirrhosis, Volume 5, Issue 1, Page 65-95, March 2026.Primary liver cancer remains a major global health burden, with China accounting for over 40% of cases. The predominant etiology is shifting from viral hepatitis to metabolic dysfunction‐associated steatotic liver disease (MASLD), while aflatoxin exposure and unhealthy lifestyles remain important contributors. Comprehensive control strategies—including
Jiayan Yan +12 more
wiley +1 more source
Chronic hepatitis in horses with persistent equine hepacivirus infection
Equine Veterinary Journal, Volume 58, Issue 2, Page 444-457, March 2026.Abstract Background Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited. Objectives To report 19 cases of chronic hepatitis and persistent EqHV infection.
Mason C. Jager +13 more
wiley +1 more source